Brand Name
Comtan
Generic Name
Entacapone
View Brand Information FDA approval date: April 01, 2013
Classification: Catechol-O-Methyltransferase Inhibitor
Form: Tablet
What is Comtan (Entacapone)?
Entacapone tablets USP are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose "wearing-off" in patients with Parkinson's disease. Entacapone's effectiveness has not been systematically evaluated in patients with Parkinson's disease who do not experience end-of-dose "wearing-off.
Approved To Treat
Top Global Experts
There are no experts for this drug
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment
Related Latest Advances
There is no latest advances for this treatment